Document Type : Original Article


1 Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran

2 Neurological Surgery Ward, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran


Background: Despite special global considerations which have been made to prioritize vaccination of people with multiple sclerosis (MS), some are reluctant to get vaccinated. This study was aimed to evaluate the attitude toward coronavirus disease-2019 (COVID-19) vaccine and its probable correlations.
Methods: Considering the study objectives, two valid questionnaires including Fear of COVID-19 Scale (FCV-19S) and attitude questionnaires were administered pre and post COVID-19 vaccination among people with MS.
Results: The questionnaires were administered among 349 people with MS pre and post vaccination. The mean age of participants was 38.78 ± 8.68 (range: 19 to 64) years. They all received the first dose of COVID-19 vaccine (Sinopharm). Although about 90% of participants felt satisfied after getting vaccinated and respected the preventive actions like social distancing and wearing face mask after vaccination, about 40% of them did not recommend vaccination to other patients. None of the demographic data was predictor of attitude score in COVID-19 vaccine and the only effective factor regarding fear of COVID-19 among people with MS was gender (P = 0.001). 
It was found that the more a patient’s fear score was, the more he/she felt satisfied after vaccination. Those patients who had got the influenza vaccine last year felt more satisfied with the vaccine and accepted the COVID-19 vaccine easier than others.
Conclusion: This study revealed that there was an inverse correlation between fear of coronavirus and less trust in the vaccine in patients with MS. However, it should be mentioned that the patients felt more satisfied after COVID-19 vaccination.


  1. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents 2020; 55(6): 105948.
  2. Giovannoni G, Hawkes C, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 2020; 39: 102073.
  3. Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, et al. COVID-19 in Patients with multiple sclerosis: Associations with disease-modifying therapies. CNS Drugs 2021; 35(3): 317-30.
  4. Sharifian-Dorche M, Sahraian MA, Fadda G, Osherov M, Sharifian-Dorche A, Karaminia M, et al. COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review. Mult Scler Relat Disord 2021; 50: 102800.
  5. Sahraian MA, Azimi A, Navardi S, Ala S, Naser MA. Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2020; 46: 102472.
  6. Al Jumah M, Abulaban A, Aggad H, Al Bunyan R, AlKhawajah M, Al Malik Y, et al. Managing multiple sclerosis in the Covid19 era: A review of the literature and consensus report from a panel of experts in Saudi Arabia. Mult Scler Relat Disord 2021; 51: 102925.
  7. Fallahi-Khoshknab M, Ghafari S, Nourozi K, Mohammadi E. Confronting the diagnosis of multiple sclerosis: A qualitative study of patient experiences. J Nurs Res 2014; 22(4): 275-82.
  8. Possa MF, Minacapelli E, Canale S, Comi G, Martinelli V, Falautano M. The first year after diagnosis: Psychological impact on people with multiple sclerosis. Psychol Health Med 2017; 22(9): 1063-71.
  9. Hunter R, Parry B, Thomas C. Fears for the future: A qualitative exploration of the experiences of individuals living with multiple sclerosis, and its impact upon the family from the perspective of the person with MS. Br J Health Psychol 2021; 26(2): 464-81.
  10. Broche-Perez Y, Jimenez-Morales RM, Monasterio-Ramos LO, Vazquez-Gomez LA, Fernandez-Fleites Z. Fear of COVID-19, problems accessing medical appointments, and subjective experience of disease progression, predict anxiety and depression reactions in patients with Multiple Sclerosis. Mult Scler Relat Disord 2021; 53: 103070.
  11. Ramezani N, Ashtari F, Bastami EA, Ghaderi K, Hosseini SM, Naeini MK, et al. Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population. Mult Scler Relat Disord 2021; 50: 102798.
  12. Shaygannejad V, Mirmosayyeb O, Nehzat N, Ghajarzadeh M. Fear of relapse, social support, and psychological well-being (depression, anxiety, and stress level) of patients with multiple sclerosis (MS) during the COVID-19 pandemic stage. Neurol Sci 2021; 42(7): 2615-8.
  13. Rezaeimanesh N, Sahraian MA, Naser MA. Evaluation of the opinion of patients with multiple sclerosis on the outcomes of catching COVID-19 and its effects on the MS symptoms. Basic Clin Neurosci 2020; 11(2): 201-6.
  14. Diem L, Friedli C, Chan A, Salmen A, Hoepner R. Vaccine hesitancy in patients with multiple sclerosis: Preparing for the SARS-CoV-2 vaccination challenge. Neurol Neuroimmunol Neuroinflamm 2021; 8(3): e991.
  15. Abbasi N, Ghadiri F, Moghadasi AN, Azimi A, Navardi S, Heidari H, et al. COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis. Mult Scler Relat Disord 2022; 60: 103723.
  16. Serrazina F, Sobral PA, Cabral G, Salavisa M, Correia AS. Willingness to be vaccinated against COVID-19: An exploratory online survey in a Portuguese cohort of multiple sclerosis patients. Mult Scler Relat Disord 2021; 51: 102880.
  17. Xiang XM, Hollen C, Yang Q, Brumbach BH, Spain RI, Wooliscroft L. COVID-19 vaccination willingness among people with multiple sclerosis. Mult Scler J Exp Transl Clin 2021; 7(2): 20552173211017159.
  18. Baraniuk C. What do we know about China's covid-19 vaccines? BMJ 2021; 373: n912.
  19. Ahorsu DK, Lin CY, Imani V, Saffari M, Griffiths MD, Pakpour AH. The Fear of COVID-19 Scale: Development and initial validation. Int J Ment Health Addict 2022; 20(3): 1537-45.
  20. Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: A web-based national survey. J Multidiscip Healthc 2020; 13: 1657-63.
  21. Ghadiri F, Sahraian MA, Saeedi R, Naser MA. Attitudes toward vaccination in patients with multiple sclerosis: A report from Iran. Mult Scler Relat Disord 2021; 53: 103045.
  22. Dorman C, Perera A, Condon C, Chau C, Qian J, Kalk K, et al. Factors associated with willingness to be vaccinated against COVID-19 in a large convenience Sample. J Community Health 2021; 46(5): 1013-9.
  23. Skovgaard L. Use and users of complementary and alternative medicine among people with multiple sclerosis in Denmark. Dan Med J 2016; 63(1): B5159.
  24. Jennings W, Stoker G, Bunting H, Valgarethsson VO, Gaskell J, Devine D, et al. Lack of trust, conspiracy beliefs, and social media use predict COVID-19 vaccine hesitancy. Vaccines (Basel) 2021; 9(6).
  25. Moulin AM. French specificities in the history of vaccination. The end of an exception?. Rev Epidemiol Sante Publique 2006; 54(Spec No 1): 1S81-7. [In French].
  26. Piyasirisilp S, Hemachudha T. Neurological adverse events associated with vaccination. Curr Opin Neurol 2002; 15(3): 333-8.
  27. Moniz DJ, Santos M, Rodrigues AM, Rego A, Vitor J, Delgado S, et al. Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine. Mult Scler Relat Disord 2021; 54: 103113.
  28. Capuano R, Altieri M, Bisecco A, d'Ambrosio A, Docimo R, Buonanno D, et al. Psychological consequences of COVID-19 pandemic in Italian MS patients: Signs of resilience? J Neurol 2021; 268(3): 743-50.
  29. Stojanov A, Malobabic M, Milosevic V, Stojanov J, Vojinovic S, Stanojevic G, et al. Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak. Mult Scler Relat Disord 2020; 45: 102407.
  30. Latkin CA, Dayton L, Yi G, Konstantopoulos A, Boodram B. Trust in a COVID-19 vaccine in the U.S.: A social-ecological perspective. Soc Sci Med 2021; 270: 113684.
  31. Schernhammer E, Weitzer J, Laubichler MD, Birmann BM, Bertau M, Zenk L, et al. Correlates of COVID-19 vaccine hesitancy in Austria: Trust and the government. J Public Health (Oxf) 2022; 44(1): e106-e116.
  32. Saeedi R, Rezaeimanesh N, Sahraian MA, Moghadasi AN. The possible direct correlation between cognitive impairment and fear of catching COVID-19 among patients with multiple sclerosis. Iran J Psychiatry 2021; 16(3): 336-42.
  33. Ghajarzadeh M, Naser Moghadasi A, Navardi S, Mohammadi A, Hamtaee S, Sahraian MA, et al. Attitude and knowledge of patients with multiple sclerosis (MS) about covid-19 as provided by physicians. Arch Neurosci 202; 8(1): e112867.
  34. Sahraian MA, Gheini MR, Rezaeimanesh N, Ghajarzadeh M, Naser MA. Knowledge regarding COVID-19 pandemic in patients with multiple sclerosis (MS): A report from Iran. Mult Scler Relat Disord 2020; 42: 102193.
  35. Broche-Perez Y, Fernandez-Fleites Z, Jimenez-Puig E, Fernandez-Castillo E, Rodriguez-Martin BC. Correction to: Gender and fear of COVID-19 in a Cuban Population Sample. Int J Ment Health Addict 2022; 20(1): 83–91.
  36. Gostin LO, Salmon DA. The Dual epidemics of COVID-19 and Influenza: Vaccine acceptance, coverage, and mandates. JAMA 2020; 324(4): 335-6.
  37. Kwok KO, Li KK, Wei WI, Tang A, Wong SYS, Lee SS. Editor's choice: Influenza vaccine uptake, COVID-19 vaccination intention and vaccine hesitancy among nurses: A survey. Int J Nurs Stud 2021; 114: 103854.